Patents by Inventor Gisele Nishiguchi
Gisele Nishiguchi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240132463Abstract: In one aspect, the disclosure relates to substituted N-(2-(2,6-dioxopiperidinyl-3-yl)-1,3-dioxoisoindolin-5-yl)arylsulfonamide analogs that useful as modulators of cereblon (CRBN) activity, methods of making same, pharmaceutical compositions comprising same, and methods of treating various clinical conditions and disorders using same, e.g., a disorder of uncontrolled cellular proliferation, such as a cancer, which may be associated with cereblon protein dysfunction and/or a GSPT1 dysfunction. In various further aspects, the disclosed compounds can selectively modulate the degradation of GSPT1 protein, i.e., the disclosed compounds can act as GSPT1 degraders. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.Type: ApplicationFiled: September 14, 2023Publication date: April 25, 2024Inventors: Marcus FISHER, Fatemeh KERAMATNIA, Kevin MCGOWAN, Jaeki MIN, Gisele A. NISHIGUCHI, Jeanine PRICE, Zoran RANKOVIC, Sourav Das, Charles G. MULLIGHAN, Yunchao CHANG
-
Publication number: 20220274948Abstract: In one aspect, the disclosure relates to substituted N-(2-(2,6-dioxopiperidinyl-3-yl)-1,3-dioxoisoindolin-5-ypaiylsulfo namide analogs that useful as modulators of cereblon (CRBN) activity, methods of making same, pharmaceutical compositions comprising same, and methods of treating various clinical conditions and disorders using same, e.g., a disorder of uncontrolled cellular proliferation, such as a cancer, which may be associated with cereblon protein dysfunction and/or a GSPT1 dysfunction. In various further aspects, the disclosed compounds can selectively modulate the degradation of GSPT1 protein, i.e., the disclosed compounds can act as GSPT1 degraders. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.Type: ApplicationFiled: May 9, 2022Publication date: September 1, 2022Inventors: Marcus FISHER, Fatemeh KERAMATNIA, Kevin MCGOWAN, Jaeki MIN, Gisele A. NISHIGUCHI, Jeanine PRICE, Zoran RANKOVIC, Das SOURAV, Charles G. MULLIGHAN, Yunchao CHANG
-
Patent number: 10709712Abstract: The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.Type: GrantFiled: February 12, 2019Date of Patent: July 14, 2020Assignee: NOVARTIS AGInventors: Robert John Aversa, Paul Andrew Barsanti, Matthew T. Burger, Michael Patrick Dillon, Alan Dipesa, Cheng Hu, Yan Lou, Gisele A. Nishiguchi, Yue Pan, Valery Rostislavovich Polyakov, Savithri Ramurthy, Alice C. Rico, Lina Quattrocchio Setti, Aaron Smith, Sharadha Subramanian, Benjamin R. Taft, Huw Roland Tanner, Lifeng Wan, Naeem Yusuff
-
Patent number: 10392404Abstract: The present invention provides compounds of Formula (I) and (II) as described herein, and salts thereof and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.Type: GrantFiled: September 11, 2015Date of Patent: August 27, 2019Assignee: Novartis AGInventors: Paul Andrew Barsanti, Matthew T. Burger, Yan Lou, Gisele A. Nishiguchi, Valery Rostislavovich Polyakov, Savithri Ramurthy, Sharadha Subramanian, Benjamin R. Taft, Huw Rowland Tanner, Lifeng Wan
-
Publication number: 20190175606Abstract: The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.Type: ApplicationFiled: February 12, 2019Publication date: June 13, 2019Inventors: Robert John AVERSA, Paul Andrew BARSANTI, Matthew T. BURGER, Michael Patrick DILLON, Alan DIPESA, Cheng HU, Yan LOU, Gisele A. NISHIGUCHI, Yue PAN, Valery Rostislavovich POLYAKOV, Savithri RAMURTHY, Alice C. RICO, Lina Quattrocchio SETTI, Aaron SMITH, Sharadha SUBRAMANIAN, Benjamin R. TAFT, Huw Roland TANNER, Lifeng WAN, Naeem YUSUFF
-
Patent number: 10245267Abstract: The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.Type: GrantFiled: May 22, 2017Date of Patent: April 2, 2019Assignee: Novartis AGInventors: Robert John Aversa, Paul Andrew Barsanti, Matthew T. Burger, Michael Patrick Dillon, Alan Dipesa, Cheng Hu, Yan Lou, Gisele A. Nishiguchi, Yue Pan, Valery Rostislavovich Polyakov, Savithri Ramurthy, Alice C. Rico, Lina Quattrocchio Setti, Aaron Smith, Sharadha Subramanian, Benjamin R. Taft, Huw Roland Tanner, Lifeng Wan, Naeem Yusuff
-
Patent number: 10167279Abstract: The present invention provides compounds of Formula (I) and (II) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.Type: GrantFiled: September 11, 2015Date of Patent: January 1, 2019Assignee: Novartis AGInventors: Robert John Aversa, Matthew T. Burger, Michael Patrick Dillon, Thomas A. Dineen, Jr., Yan Lou, Gisele A. Nishiguchi, Savithri Ramurthy, Alice C. Rico, Vivek Rauniyar, Martin Sendzik, Sharadha Subramanian, Lina Quattrocchio Setti, Benjamin R. Taft, Huw Rowland Tanner, Lifeng Wan
-
Publication number: 20180170917Abstract: The present invention provides compounds of Formula (I) and (II) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.Type: ApplicationFiled: September 11, 2015Publication date: June 21, 2018Inventors: Robert John AVERSA, Matthew T. BURGER, Michael Patrick DILLON, Thomas A. DINEEN, Jr., Yan LOU, Gisele A. NISHIGUCHI, Savithri RAMURTHY, Alice C. RICO, Vivek RAUNIYAR, Martin SENDZIK, Sharadha SUBRAMANIAN, Lina Quattrocchio SETTI, Benjamin R. TAFT, Huw Rowland TANNER, Lifeng WAN
-
Publication number: 20170260207Abstract: The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.Type: ApplicationFiled: May 22, 2017Publication date: September 14, 2017Inventors: Robert John AVERSA, Paul Andrew BARSANTI, Matthew T. BURGER, Michael Patrick DILLON, Alan DIPESA, Cheng HU, Yan LOU, Gisele A. NISHIGUCHI, Yue PAN, Valery Rostislavovich POLYAKOV, Savithri RAMURTHY, Alice C. RICO, Lina Quattrocchio SETTI, Aaron SMITH, Sharadha SUBRAMANIAN, Benjamin R. TAFT, Huw Roland TANNER, Lifeng WAN, Naeem YUSUFF
-
Publication number: 20170260200Abstract: The present invention provides compounds of Formula (I) and (II) as described herein, and salts thereof and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.Type: ApplicationFiled: September 11, 2015Publication date: September 14, 2017Inventors: Paul Andrew BARSANTI, Matthew T. BURGER, Yan LOU, Gisele A. NISHIGUCHI, Valery Rostislavovich POLYAKOV, Savithri RAMURTHY, Sharadha SUBRAMANIAN, Benjamin R. TAFT, Huw Rowland TANNER, Lifeng WAN
-
Patent number: 9694016Abstract: The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.Type: GrantFiled: March 13, 2014Date of Patent: July 4, 2017Assignee: NOVARTIS AGInventors: Robert John Aversa, Paul Andrew Barsanti, Matthew Burger, Michael Patrick Dillon, Alan Dipesa, Cheng Hu, Yan Lou, Gisele Nishiguchi, Yue Pan, Valery Polyakov, Savithri Ramurthy, Alice Rico, Lina Setti, Aaron Smith, Sharadha Subramanian, Benjamin Taft, Huw Tanner, Lifeng Wan, Naeem Yusuff
-
Publication number: 20160038504Abstract: The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.Type: ApplicationFiled: March 13, 2014Publication date: February 11, 2016Applicant: NOVARTIS AGInventors: Robert AVERSA, Paul A. BARSANTI, Matthew BURGER, Michael Patrick DILLON, Alan DIPESA, Cheng HU, Yan LOU, Gisele NISHIGUCHI, Yue PAN, Valery POLYAKOV, Savithri RAMURTHY, Alice RICO, Lina SETTI, Aaron SMITH, Sharadha SUBRAMANIAN, Benjamin TAFT, Huw TANNER, Lifeng WAN, Naeem YUSUFF
-
Patent number: 9242969Abstract: The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.Type: GrantFiled: March 11, 2014Date of Patent: January 26, 2016Assignee: Novartis AGInventors: Paul A. Barsanti, Matthew Burger, Yan Lou, Gisele Nishiguchi, Valery Polyakov, Savithri Ramurthy, Alice Rico, Lina Setti, Aaron Smith, Benjamin Taft, Huw Tanner, Alan DiPesa, Naeem Yusuff
-
Publication number: 20150336960Abstract: The present invention provides a compound of formula (I) as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula (I), and pharmaceutical compositions comprising such compounds.Type: ApplicationFiled: December 7, 2013Publication date: November 26, 2015Applicant: NOVARTIS AGInventors: Matthew BURGER, Gisele NISHIGUCHI, Alice RICO, Benjamin TAFT
-
Publication number: 20150315150Abstract: New compounds, compositions and methods of inhibition of Provirus Integration of Maloney Kinase (PIM kinase) activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one PIM kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.Type: ApplicationFiled: July 13, 2015Publication date: November 5, 2015Applicant: Novartis AGInventors: Matthew T. Burger, Wooseok Han, Jiong Lan, Gisele Nishiguchi
-
Patent number: 9173883Abstract: The present invention provides a compound of formula (A): as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula I, and pharmaceutical compositions comprising such compounds.Type: GrantFiled: May 20, 2013Date of Patent: November 3, 2015Assignee: NOVARTIS AGInventors: Matthew Burger, Joseph E. Drumm, III, Gisele Nishiguchi, Alice Rico, Robert Lowell Simmons, Benjamin Taft, Huw Tanner
-
Patent number: 9079889Abstract: New compounds, compositions and methods of inhibition of Provirus Integration of Maloney Kinase (PIM kinase) activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one PIM kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.Type: GrantFiled: November 15, 2013Date of Patent: July 14, 2015Assignee: NOVARTIS AGInventors: Matthew T. Burger, Wooseok Han, Jiong Lan, Gisele Nishiguchi
-
Publication number: 20150150873Abstract: The present invention provides a compound of formula (A): as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula I, and pharmaceutical compositions comprising such compounds.Type: ApplicationFiled: February 12, 2015Publication date: June 4, 2015Inventors: Matthew Burger, Joseph E. Drumm III, Gisele Nishiguchi, Alice Rico, Robert Lowell Simmons, Benjamin Taft, Huw Tanner
-
Publication number: 20150133473Abstract: The present invention provides a compound of formula (A): as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula I, and pharmaceutical compositions comprising such compounds.Type: ApplicationFiled: May 20, 2013Publication date: May 14, 2015Applicant: NOVARTIS AGInventors: Matthew Burger, Joseph E. Drumm III, Gisele Nishiguchi, Alice Rico, Robert Lowell Simmons, Benjamin Taft, Huw Tanner
-
Patent number: 8987457Abstract: The present invention provides a compound of formula (A): as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula I, and pharmaceutical compositions comprising such compounds.Type: GrantFiled: May 20, 2013Date of Patent: March 24, 2015Assignee: Novartis AGInventors: Matthew Burger, Joseph E. Drumm, III, Gisele Nishiguchi, Alice Rico, Robert Lowell Simmons, Benjamin Taft, Huw Tanner